Patient Perception of Visual Quality and Function
1 other identifier
observational
301
1 country
1
Brief Summary
The purpose of this study is to evaluate the visual quality and function of pseudophakic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2014
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 20, 2014
CompletedFirst Posted
Study publicly available on registry
May 26, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2014
CompletedResults Posted
Study results publicly available
September 7, 2015
CompletedSeptember 28, 2015
September 1, 2015
2 months
May 20, 2014
July 7, 2015
September 10, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Use of Corrective Visual Aids (i.e., Spectacles, Contact Lenses) Post Intraocular Lens (IOL) Surgery
Patients will be assessed at a baseline visit and a visit 1 week later to determine their use of corrective visual aids (i.e., spectacles, contact lenses) post Intraocular Lens (IOL) surgery.
Baseline and 1 week
Study Arms (1)
Pseudophakic
Interventions
Eligibility Criteria
Bilaterally-implanted pseudophakic subjects over 22 years of age who meet the inclusion criteria.
You may qualify if:
- Minimum 22 years of age
- Pseudophakic patients who have been bilaterally implanted with the same type of intraocular lenses in both eyes
- Ability to understand, read and write English to give consent and complete the study questionnaires
- Availability, willingness, and sufficient cognitive awareness to comply with examination procedures and study visits
- Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
You may not qualify if:
- Any ocular pathology of clinical significance, as determined by the investigator, that may affect visual outcomes or influence subjective ocular/visual symptoms
- Patient is pregnant or is lactating
- Concurrent participation or participation within 30 days prior in any other clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Daniel Chang, M.D.
Bakersfield, California, 93309, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Anne Buteyn; Manager, Clinical Research
- Organization
- Abbott Medical Optics
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2014
First Posted
May 26, 2014
Study Start
May 1, 2014
Primary Completion
July 1, 2014
Study Completion
July 1, 2014
Last Updated
September 28, 2015
Results First Posted
September 7, 2015
Record last verified: 2015-09